The effects of oral factor Xa inhibitors and oral thrombin inhibitors on tests for hereditary thrombophilia
| Thrombophilia . | Tests . | Effect on test . |
|---|---|---|
| Factor V Leiden mutation | PCR | Not affected |
| Prothrombin G20210A mutation | PCR | Not affected |
| Protein C deficiency | Protein C activity: clot-based assays | Interference by oral factor Xa inhibitors and dabigatran |
| Protein C activity: amidolytic assays | Not affected | |
| Protein C antigen assays | Not affected | |
| Protein S deficiency | Protein S activity: clot-based assays | Interference by oral factor Xa inhibitors and dabigatran |
| Protein S antigen assays | Not affected | |
| Antithrombin deficiency | Antithrombin activity: anti-Xa–based assays | Interference by oral factor Xa inhibitors |
| Antithrombin activity: anti-IIa–based assays | Interference by dabigatran | |
| Antithrombin antigen assays | Not affected |
| Thrombophilia . | Tests . | Effect on test . |
|---|---|---|
| Factor V Leiden mutation | PCR | Not affected |
| Prothrombin G20210A mutation | PCR | Not affected |
| Protein C deficiency | Protein C activity: clot-based assays | Interference by oral factor Xa inhibitors and dabigatran |
| Protein C activity: amidolytic assays | Not affected | |
| Protein C antigen assays | Not affected | |
| Protein S deficiency | Protein S activity: clot-based assays | Interference by oral factor Xa inhibitors and dabigatran |
| Protein S antigen assays | Not affected | |
| Antithrombin deficiency | Antithrombin activity: anti-Xa–based assays | Interference by oral factor Xa inhibitors |
| Antithrombin activity: anti-IIa–based assays | Interference by dabigatran | |
| Antithrombin antigen assays | Not affected |
PCR, polymerase chain reaction.